부산대학교 도서관

Thirteen children with refractory or recurrent Hodgkin's lymphoma (HL) received high-dose chemotherapy and autologous hematopoietic stem cell transplant (ASCT). After hematologic recovery, 10 patients were given interferon-[alpha] (IFN-[alpha]) as adjuvant therapy, starting at a dose of 0.5 x 10[sup.6] U/m[sup.2] subcutaneously, three times a week. The dose was escalated as tolerated. Patients were treated for a median of 12 (4-24) months. Transient myelosuppression was the most common toxicity and led to temporary treatment interruption in five patients. The IFN-[alpha] dose was increased in nine patients, to a median final dose of 3.5 x 10[sup.6] U/m[sup.2]/week. With a median follow-up of 67 (range 25-114) months, nine of the 10 patients are alive and in continuous remission. One patient relapsed. Three patients were not treated with IFN-[alpha] initially, two because of rapidly progressive disease. One patient received IFN-[alpha] for treatment of relapse after transplant, and is alive in remission 10 years later. IFN-[alpha] has activity in children with advanced HL, and prolonged, low-dose treatment given after ASCT can be tolerated. Its therapeutic effect as a post-transplant adjuvant warrants further investigation. Bone Marrow Transplantation (2006) 38, 345-349. doi: 10.1038/sj.bmt.1705458 Keywords: Hodgkin's lymphoma, autologous stem cell transplant, interferon-[alpha], children
Author(s): D Petropoulos [1]; L L Worth [1]; C A Mullen [1, 2]; S Lockhart [3]; M Choroszy [1]; K W Chan [1, 4] Introduction Whereas the outcome of Hodgkin's [...]